Máj- és epeúti rák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PD-1 91
• PD-L1 51
• TP53 3
• PI3K 0
• mTOR 1
• AKT 0
• STAT3 1
• VEGF 20
• FGFR 22
• GPC3 38
• CTNNB1 5
• YAP 0
• MAPK 0
• HER2 28
• NRF2 0
• HIF-1 0
• PPAR 0
• ERK 0
• AMPK 0
• STING 0
• EGFR 8
• CTLA-4 19
• MYC 0
• IDH 6
• JAK 0
• JNK 0
• PTEN 0
• GPX4 0
• KRAS 8
• BCL-2 0
• HSP90 0
• IL-6 1
• PSMA 8
• MET 1
• GLP-1 1
• BRAF 3
• EZH2 0
• NLRP3 0
• CLDN18 10
• MEK 0
• B7-H3 5
• COX-2 0
• HDAC 0
• CXCR4 0
• HMGB1 0
• METTL3 0
• SIRT1 0
• TLR4 0
• MMP-9 0
• TNF 0
• PARP 2
• PCSK9 0
• TIGIT 2
• TIM-3 1
• IL-17 0
• RAS 2
• SGLT2 0
• CD47 0
• CDK4/6 0
• IL-15 2

4054 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glutaminase Isoenzymes: Gatekeepers of Bioenergetics, Immunity, and Tumor Microenvironment in Diabetes-Induced Hepatocellular Carcinoma (IRM)

  Fundacion Para la Investigacion de Malaga En Biomedicina y Salud· Malaga, Spanyolország· EU contribution 209 915 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding Neural Circuits in Cholangiocarcinoma (LIVER-CIRCUITS)

  Technische Universitaet Dresden· Dresden, Németország· EU contribution 1 500 000 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling Malignant Cholangiocyte Subpopulations that Drive Chemoresistance in Cholangiocarcinoma (RESIST-CCA)

  Humanitas Mirasole Spa· Rozzano (Mi), Olaszország· EU contribution 193 643 EUR· until 2028. dec.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Multiscale 3D virtual histology with non-destructive x-rays (XHIST)

  Danmarks Tekniske Universitet· Kongens Lyngby, Dánia· EU contribution 150 000 EUR· until 2028. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Mechano-metabOlic Responsive nanoPlatform for HeterogEnous tUmor Suppression (MORPHEUS)

  Fundacion de la Comunidad Valenciana Centro de Investigacion Principe Felipe· Valencia, Spanyolország· EU contribution 2 499 745 EUR· until 2031. aug.

  The disease is named only in the funder's project summary, not in the title.

5 of 39 running projects, newest first. Listed amounts together: 133,0 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

  NCT05075993· M.D. Anderson Cancer Center· Frissítve: 2026. nov. 10.

  “\<75% participation”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  CT-95 in Advanced Cancers Associated With Mesothelin Expression

  NCT06756035· Context Therapeutics Inc.· Frissítve: 2026. nov. 5.

  “The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer

  NCT05065957· InnoPharmax Inc.· Frissítve: 2026. nov. 4.

  “Dose-finding stage has been completed, and dose-expanding stage was not conducted due to design amendment.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)

  NCT06487559· AbbVie· Frissítve: 2026. okt. 21.

  “Strategic considerations”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

  NCT07146646· Case Comprehensive Cancer Center· Frissítve: 2026. okt. 20.

  “Interim Analysis”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

  NCT05879822· Incyte Corporation· Frissítve: 2026. okt. 20.

  “This was a strategic business decision. There were no safety concerns contributing to this decision.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma

  NCT07274774· Shandong Cancer Hospital and Institute· Frissítve: 2026. okt. 15.

  “Difficult to recruit patients”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

  NCT06091930· Boehringer Ingelheim· Frissítve: 2026. okt. 14.

  “Sponsor decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization

  NCT07178093· Taichung Tzu Chi Hospital· Frissítve: 2026. okt. 6.

  “poor accrual and insufficient drug supply”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Study of PTX-9908 Injection for Non-resectable HCC With TACE

  NCT03812874· TCM Biotech International Corp.· Frissítve: 2026. okt. 2.

  “Due to business considerations and challenges in participant recruitment, the Sponsor has decided to discontinue the study.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

  NCT04907643· Cedars-Sinai Medical Center· Forrás

• Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

  NCT05564403· National Cancer Institute (NCI)· Forrás

• Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy

  NCT07715903· National Cancer Institute (NCI)· Forrás

• Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

  NCT04068194· National Cancer Institute (NCI)· Forrás

• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

  NCT04491942· National Cancer Institute (NCI)· Forrás

• A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)

  2025-524160-38-00· Merck Sharp & Dohme LLC· Forrás

• Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma

  NCT07836530· BeOne Medicines· Forrás

• A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

  NCT06066138· National Cancer Institute (NCI)· Forrás

• Collection of Blood From Patients With Cancer

  NCT00034216· National Cancer Institute (NCI)· Forrás

• Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies

  NCT00451022· National Cancer Institute (NCI)· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 109
• Organoids 40
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 34
• Gene Expression Profiling 281
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 9
• Exome Sequencing 19
• Proteomics 119
• Metabolomics 73
• Mass Spectrometry 23
• Flow Cytometry 66
• Immunohistochemistry 125
• Liquid Biopsy 34
• Circulating Tumor DNA 41
• Xenograft Model Antitumor Assays 443
• Positron-Emission Tomography 35
• Magnetic Resonance Imaging 376
• Machine Learning 198
• Deep Learning 114
• Cohort Studies 184
• Genome-Wide Association Study 42

• Whole-genome sequencing in Brazilian patients with neurofibromatosis type 1, including novel variants, incidental findings, and dual diagnoses.

  Einstein (Sao Paulo), 2026. júl.

• Clonorchis sinensis infection alters the methylation and hydroxymethylation of hepatocellular carcinoma.

  Front Cell Infect Microbiol, 2026. júl.

• Noninvasive detection and prognostic stratification of biliary tract cancer using cell-free DNA fragmentomics: a model development and validation study.

  Mol Biomed, 2026. máj.

• Whole-Genome Bisulfite Sequencing Identifies Blood-Based DNA Methylation Biomarker for Hepatocellular Carcinoma.

  Mol Carcinog, 2026. márc.

• Genomic and transcriptomic profiling of hepatocellular carcinoma in patients with Fontan-associated liver disease.

  Hepatology, 2026. jan.

• Clinicogenomic Characterization of Primary Sclerosing Cholangitis-Associated Biliary Tract Cancers.

  Clin Cancer Res, 2026. jan.

• Whole-Genome Analysis of Ralstonia mannitolilytica in a Patient with Hepatocellular Carcinoma.

  Microb Drug Resist, 2026. jan.

• Evaluation of Raw Cell-Free DNA Sequences for Gastric Cancer Detection.

  JCO Precis Oncol, 2025. nov.

• Whole genome bisulfite sequencing reveals epigenetic drivers of chronic chlorpyrifos exposure induced liver cell neoplasia.

  J Hazard Mater, 2025. nov.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.